Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients - Wikidata - wikimedia - TriplyDB

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients

http://www.wikidata.org/entity/Q36977382

about

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Safety concerns about intravenous iron therapy in patients with chronic kidney disease Safety of intravenous iron formulations: facts and folklore Considerations and challenges in defining optimal iron utilization in hemodialysis Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study Safety of intravenous iron in hemodialysis patients.Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.Iron and infection in hemodialysis patients Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.Intravenous iron exposure and mortality in patients on hemodialysis Iron supplementation and mortality in incident dialysis patients: an observational study.Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis.Iron dosing in kidney disease: inconsistency of evidence and clinical practice.Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection.Trends in Anemia Management in Hemodialysis Patients with Cancer Counterpoint: the treatment decision design Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.The Labile Side of Iron Supplementation in CKD Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn).Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.Clinical practice guidelines on iron therapy: A critical evaluation.Ferric pyrophosphate: good things come to those who wait?Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.Intravenous iron administration strategies and anemia management in hemodialysis patients.We Give Too Much Intravenous Iron.Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry.Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.Current misconceptions in diagnosis and management of iron deficiency Intravenous iron exposure and outcomes in patients on hemodialysis.Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.

P2860

Q26752664-B25875A7-00F1-4931-B653-647C48B52D29 Q26764881-FF48E0D3-31FF-4B65-8136-13E94C8D41A2 Q26853397-6AD7941C-1EBA-4A13-9FE5-BB87639C974C Q28088564-488527FB-11FF-472E-9B7B-B4338E558268 Q28646953-1A48950E-3056-41CD-9CA8-2C32C743E9BC Q30234981-44EE4052-300B-4B1E-83CA-4AB9F85A785D Q30588674-4301894B-0226-4C7D-8D1C-AA852450748A Q33591327-C89C0CB8-7B94-453D-B13A-F0809376CC7B Q33853010-632BBD4B-4122-4F10-AA31-EB5D6068D355 Q34455198-F4BEA3CA-E848-4E8D-8387-C758835EB627 Q34612274-24E901BD-4288-4222-BF25-BDE623D84937 Q34704499-971DCA66-4933-4C2F-BAD6-1377E22250A5 Q35022235-5FD3E78D-C38F-4801-B01B-857810013F35 Q35474305-C1DAEFA9-989A-43FE-B446-4AFCB39B1340 Q35998091-3C85E25B-25B9-47C2-B4BB-903102C84D47 Q36104846-9EACACCD-6CF9-4A59-8AD8-3C71BD740FC7 Q36123593-DFE65595-B4CE-4BF0-9CB6-537C951C5AC3 Q36200205-2C0A8A7B-53A1-45BE-9B3B-15CA85EAEE70 Q36251759-1BF7E446-A7A8-4B83-9AAB-5D8BB3C48944 Q36315311-80A13634-6086-402C-98F5-35B98C8DBC00 Q36790975-9C8DE796-EDB9-45FE-BD3F-9FE9D8D342A9 Q37045476-01F1BCC3-3678-4A14-9B23-7C198C3B8981 Q38245887-6305E366-057E-4369-ADFC-32C0A16F8A2B Q38496987-8D4E0187-0718-4F23-B804-1A612DD09947 Q38761669-7F7F4C1B-1174-41D7-9454-B6462EF2167A Q39022863-5B905A9D-CB2B-474E-BA75-7D9D24AA115A Q39034275-150CA07C-502F-4FC8-8389-E87EB3820321 Q39258133-E261B6EF-1F95-45EC-B4FC-C58EE6B30043 Q40219761-4D7C50F4-4CE5-4181-B12A-C4DFAA929B38 Q40469488-6F376E89-8592-4FB4-B096-A14F0A279C68 Q40526919-92920401-A452-47B0-A047-E72C22059D9D Q40548437-5EB19447-519A-4F39-9493-A593D40A6EFA Q40684479-D52E7B84-8748-4E1D-A2A5-85CBEA942464 Q40813065-C263A453-83AD-4E20-889E-AB8BF664AC0E Q40886101-4E4C0CD2-820B-4D37-A4B3-97CE8C3F98B2 Q41547046-C92079F7-6CE2-42D5-959E-004519FCA002 Q42975965-D2210BE7-1BA7-4FE2-A186-CB8DDB206EA9 Q44676908-CFE02578-3731-4412-8F50-B4BD40FCB347 Q47102798-24AA2EBF-415B-469F-B0BA-0B788D486DCE Q47111895-AB8B805E-106D-4DE7-A2E8-D543B9667970

P2860

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients

http://www.wikidata.org/entity/Q36977382

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Infection risk with bolus vers ...... ation in hemodialysis patients

@en

type

label

Infection risk with bolus vers ...... ation in hemodialysis patients

@en

prefLabel

Infection risk with bolus vers ...... ation in hemodialysis patients

@en

P1433

Q36977382-9908D5F6-7DE6-48A1-8891-19B5469B4BB7

P1476

Q36977382-DAB1769C-5B67-4AC8-865E-255B64AA7859

P2093

Q36977382-21610D23-98C3-4366-900F-4ABABE9971A7

Q36977382-367CF14B-ED11-4CF3-AEEE-5F6537120783

Q36977382-3CDAC78D-87B1-4732-AAB4-6BFFDAF25F96

Q36977382-511CF5A0-9B95-4D3C-8FE5-CA1D9C3684B5

Q36977382-5413E95F-CCD4-41F6-BA45-D15A6C21EB5B

Q36977382-D6044D2E-BBD2-4117-8BC6-D70CEB45519F

P2860

Q36977382-05F5EE58-6D28-42FB-B72B-F1D71E39F8EF

Q36977382-0F11BB23-5DC8-4782-8286-29ECE8435B17

Q36977382-20A0A2E3-BE0A-4A1E-9E07-D63D54465562

Q36977382-2BFB23B9-7513-4A65-9391-3DBE9ABF7350

Q36977382-3FAAF277-342A-4B9D-874A-F2D6D46236B2

Q36977382-42952B0F-DB1A-497E-BE19-3F21732288BD

Q36977382-554D21AF-816F-4A7C-B542-DCE48930E135

Q36977382-60F807B5-BB83-4737-B926-CD66CEE818C8

Q36977382-63D343B8-4D86-4E5C-9E4D-0B4B973C17DD

Q36977382-6CD1429A-9E8D-46ED-A9B1-4426599A5F02

P304

Q36977382-81C3E272-DB47-4FC7-9DA3-DD3101D96727

P31

Q36977382-B8A8126D-D561-4CEE-A2E2-F28AD30247BA

P356

Q36977382-31917593-8559-4C2F-AA5F-2AEF6A778E00

P433

Q36977382-5E4F79F6-4451-4A94-B31C-EFE15225E825

P478

Q36977382-4A95E1B5-FD4E-4D69-846F-23F833385C22

P577

Q36977382-2E18CD34-53DE-4DA8-A5AB-32983996B7F8

P698

Q36977382-9C9E5446-6457-4AAE-B52B-5B33DCA6AC96

P932

Q36977382-F8896DD5-F179-45BE-9479-57D78D00387C

P356

P1433

Journal of the American Society of Nephrology

P1476

Infection risk with bolus vers ...... ation in hemodialysis patients

@en

P2093

Abhijit V Kshirsagar

http://www.w3.org/2001/XMLSchema#string

Alan R Ellis

http://www.w3.org/2001/XMLSchema#string

Janet K Freburger

http://www.w3.org/2001/XMLSchema#string

Lily Wang

http://www.w3.org/2001/XMLSchema#string

M Alan Brookhart

http://www.w3.org/2001/XMLSchema#string

Wolfgang C Winkelmayer

http://www.w3.org/2001/XMLSchema#string

P2860

Iron and infection.

An indistinct balance: the safety and efficacy of parenteral iron therapy.

Review of issues relating to iron and infection.

Does iron cause bacterial infections in patients with end stage renal disease?

Iron therapy for renal anemia: how much needed, how much harmful?

Iron and infection: the heart of the matter.

Intravenous iron supplementation in the anaemia of renal and cardiac failure--a double-edged sword?

Diagnosis and management of iron-related anemias in critical illness.

Intravenous iron therapy in end-stage renal disease.

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.

P304

1151-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012121164

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23787911

http://www.w3.org/2001/XMLSchema#string

P932

3699831

http://www.w3.org/2001/XMLSchema#string